Oral cancer management Flashcards

1
Q

Diagnosis of SCC - radiology (2)

A

For the ‘typical’ oral cavity SCC, Radiology is not needed for diagnosis as the clinical appearance provides the most insight
-painless ventral tongue ulcer with raised, rolled edges that is indurated (hard to palpation).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Diagnosis of lump in neck or salivary glands - radiology (3)

A

Not all of these patients will have cancer, and imaging to separate out the benign from the malignant is readily available in all Hospitals. This is usually done with ultrasound as neck lumps are often superficial, and when combined with image-guided biopsy can produce a histological diagnosis in 1 visit.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the purpose of staging? (3)

A

to accurately define the extent of the primary cancer, including the structures that it invades into as well as those structures that might be included in the resection if surgery is performed. As well as documenting the primary tumour, spread to regional lymph nodes is also evaluated, as is distant spread outside normal anatomical bounds. The almost universal standard for cancer staging is the TNM manual

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Why stage cancers? (3)

A

Staging cancers is an important process that helps to select the most appropriate treatment options, e.g. whether a curative or palliative route is planned and also whether surgery or chemoradiotherapy or combined treatment is thought to be best.
Staging also helps to predict prognosis as larger cancers with extensive lymph node spread have a poorer prognosis than smaller cancers without lymphadenopathy.
In cases of advanced disease, staging may spare the patient debilitating surgery that will not have any significant effect on survival.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

The TNM classification: T-stage (4)

A

T0: no evidence of 1° tumour
T1: ≤2cm, depth of invasion (DOI) < 5mm
T2: ≤ 2cm, DOI >5mm but ≤ 10mm OR  2cm and ≤ 4cm, DOI ≤10mm
T3: > 4cm, DOI > 10mm
T4: invades deep structures e.g. bone, masticatory muscles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

The TNM classification: N-stage (5)

A

N0: no lymph node metastases
N1: single ipsilateral node < 3cm, ENE -ve
N2a: single ipsilateral node > 3cm but < 6cm, ENE –ve
N2b: multiple ipsilateral nodes < 6cm, ENE -ve
N2c: contralateral/bilateral node(s) < 6cm, ENE -ve
N3a: any node > 6cm, ENE -ve
N3b: any node that is ENE +ve

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

The TNM classification: M-stage (2)

A

M0: no distant metastases M1: distant metastases present e.g. lung

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Extra-nodal extension (ENE) (2)

A

Spread of carcinoma though the fibrous capsule of a lymph node into the surrounding soft tissues is termed extra-nodal extension (aka extra-capsular spread). This can be detected clinically (fixation/tethering, skin invasion, cranial nerve defects) with radiological confirmation or pathologically. ENE is a new addition to the 8th Edition of the TNM manual, but has been known for some time to confer a poor-prognosis in oral cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Survival rates for mouth cancers (1)

A

Survival rates for mouth cancers have risen slightly over the last 20 years. Of all the people diagnosed with cancer of the mouth and oropharynx, 55% live for at least 5 years.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

5-year survival for

  • lip
  • tongue
  • oral cavity (3)
A

Lip: 90% survival at 5 years
Tongue: 50% survival at 5 years
Oral cavity: 47% survival at 5 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MRI vs CT (2)

A

Soft tissue resolution a lot better with MRI scans - always investigation of choice

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Prognosis significantly affected by.. (3)

A

Prognosis is significantly affected by lymph node spread - survival falls by half when comparing N0 patients to N1 patients, and again falls by half for spread to the contralateral neck (N2c). In the UK, many oral cancers still present as stage IV disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Staging of a pt with oral cancer and metastases (2) and tx (1)

A

M1 - Stage IVc
Tx will be palliative rather than curative
Distant mestastases usually occur in chest, either as spread to mediastinal LN or as lung metastases
-therefore all pts usually have some form of chest imaging in their diagnostic work up

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Surveillance (4)

A

Continued for usually 5 years
Both surgery and radiotherapy alter the appearance of the oral cavity and neck as well as it’s texture, due to scarring, which makes the detection of cancer recurrence difficult if you rely solely on the clinical examination .
Imaging helps to identify recurrent tumour, though distinguishing the effects of treatment from cancer recurrence can be very difficult. Imaging is usually with MRI and repeated imaging using the same modality can be used to monitor suspicious sites and make serial measurements.When both the clinical examination and MRI are uncertain, positron emission tomography (PET) can be used to measure glucose metabolism – cancer cells are more metabolically-active than normal cells, which can be useful to identify a site for biopsy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Role of the pathologist prior to treatment (1)

A

establish/confirm the

diagnosis; report on prognostic features

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Role of the pathologist during treatment (1)

A

provision of frozen section

diagnosis to determine completeness of excision

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Role of the pathologist after treatment (1)

A

determine completeness of

excision, report on factors important in prognosis & planning of further treatment.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Incisional biopsy - what are we looking at (3)

A
• Depth of invasion: superficial or into underlying structures?
• Pattern of invasion: are the
tumour islands cohesive or
non- cohesive?
• Degree of differentiation:
well, moderately or poorly
differentiated
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Frozen section reporting (2)

A
  • Determine whether the surgeon has completely excised the tumour
  • If not, surgeon may remove more tissue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Why is frozen section reporting controversial? (3)

A

Prolongs operation
Expensive and time consuming
May not increase pt survival/ prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

After treatment report on (2)

A

Extent of spread
• primary tumour
• any tumour present in lymphatics, blood vessels &
nerves
• tumour to lymph nodes in the neck
• from nodes into the tissues of the neck (ECS)
Completeness of excision- soft tissue & bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What are we looking at histology of tumours (3)

A
Surface diameter
Depth of invasion
Pattern of invasion:
cohesive or noncohesive
Distance of tumour from mucosal and deep excision
margins:
• >5mm = clear;
• < 5mm = close;
• <1/at margin- involved
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Final report - primary tumour (6)

A
• Diameter of tumour
• Depth &amp; pattern of
invasion
• Clearance from deep
and mucosal excision
margins
• Invasion into bone
• Clearance of bone
margins
• Lymphatic, vascular or
peri-neural invasion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Neck dissection - final report (4)

A
• Number of nodes at
each level
• Number containing
metastasis at each level
• Number showing
metastatic spread at
each level
• pTNM
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

MTD meeting (3)

A
  • Multidisciplinary Team Meeting
  • Pathologist reports on completeness of excision & other factors important in prognosis
  • Liaises with surgeons, oncologists, radiologists, speech therapists, dieticians and others about appropriate treatment.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What does head and neck cancer include? (8)

A
Larynx 
Oral cavity
Oropharynx
Hypopharynx
Nasopharynx
Major salivary gland
Nose and sinuses 
Bones of the jaw
27
Q

Role of restorative dentist MDT (2)

A

Oral Rehab
“There should be appropriate assessment of patients’ oral rehabilitative needs across the pathway and the provider must ensure that specialist oral rehabilitation is provided.”
“It is important to include a Consultant in Restorative Dentistry/Oral Rehabilitation within the head and neck cancer team as many patients face complex oral rehabilitation and dental health issues during and after their oncology treatment.”

28
Q

How many people presenting with head and neck cancer have dentists? (1)

A

<10%

29
Q

Pre-treatment assessment (2)

A

“Patients with head and neck cancer, especially those planned for resection of oral cancers or whose teeth are to be included in a radiotherapy field, should have the opportunity for a pre-treatment assessment by an appropriately experienced dental practitioner.”

30
Q

Aims of pre-treatment assessment (7)

A

Avoidance of unscheduled interruptions to primary treatment as a result of dental problems
Pre-prosthetic planning/treatment e.g., planning for primary implants/impressions for obturator
Planning for extraction of teeth which are of doubtful prognosis or are at risk of dental disease in the future and are in an area where there would be risk of osteoradionecrosis.
Extractions be carried out as early as possible in the patient journey, but as a minimum, at least 10 days prior to radiotherapy.
Planning for restoration of remaining teeth as required.
Preventive advice and treatment.
Assess potential for post treatment access difficulties e.g., trismus, microstomia.

31
Q

Short-term treatment side effects (3)

A

Mucositis: inflammation and ulceration of the mucosal lining of the oral cavity.
Infection: chemotherapy induced neutropenia makes the patient susceptible to bacterial, viral, and fungal infections. Oral candidal infections are extremely common following chemo or radiotherapy.
Xerostomia: dry mouth resulting from a decrease in the production of saliva as a result of radiotherapy.

32
Q

Long-term treatment side effects (6)

A

Altered anatomy: surgical ablation and reconstruction can cause permanent changes in oral anatomy making prosthetic rehabilitation difficult.
Rampant dental caries: Radiogenic dental caries is thought to be the result of reduced salivary flow as well as possible direct radiogenic damage to the amelodentinal junction by radiotherapy.
Trismus: may be caused by surgical scarring or by radiotherapy induced fibrosis of the masticatory muscles.
Mastication difficulties: if a significant number of opposing pairs of teeth are lost
Osteoradionecrosis: hypovascularity and necrosis of bone followed by trauma induced or spontaneous mucosal breakdown, leading to a non-healing wound.
Xerostomia - Challacombe
IMRT reduces the risk of xerostomia and may also do for osteoradionecrosis after treatment

33
Q

Preventive management for a restorative dentist of head and neck cancer(6)

A

Maintenance of good oral hygiene by effective tooth brushing; flossing daily.
Dietary Advice with regard to caries prevention.
Daily topical fluoride application (2800ppm or 5000ppm fluoride toothpaste) in custom-made trays or brush-on. Daily fluoride mouthrinse.
Daily use of GC Tooth Mousse TM containing free calcium
Saliva replacement therapy/ use of frequent saline rinses
Jaw exercises to reduce trismus (therabite).

34
Q

Aetiology of head and neck cancer (6)

A
Cigarettes
Alcohol
Lifestyle
Genetics
Virus
Hormones
35
Q

Soft tissue recon (5)

A
Radial forearm flap (RFF); 
anterolateral thigh flap (ALT); 
latissimus dorsi; 
rectus abdominus
flaps based on the scapular/para-scapular axis
36
Q

Mandibular recon (4)

A

fibula flap
deep circumflex iliac artery flap (DCIA)
scapular flap
RFF

37
Q

Rehabilitation of pt (4)

A

Multidisciplinary decision-making should include the patient, surgeon (often in conjunction with plastics) and dental prosthodontist/ restorative specialist.
Prosthetic options reduce the morbidity of treatment and can give excellent results but reconstructive options should be considered as the defect becomes larger and more complex
The choice of reconstruction or prosthetics requires discussion between the ablative, reconstructive team and the prosthodontist, maxillofacial technician, and the patient.
There are clear advantages in simplifying the surgery and using prosthetic options, but this choice becomes more difficult to deliver and for the patient to cope as the defect becomes larger and more complex.

38
Q

Implants (5)

A
Wide variation between UK centres
Pre vs Post RXT
Primary vs secondary
First line of care vs care when conventional removable failed
Fixed vs Removable ISPs
39
Q

Maxillofacial prosthesis (5)

A

Need to have a competent maxillofacial technician
Correct materials
Possible alternate application for “dental” implant
Similar prosthodontically driven tx plan
Often conducted by plastics

40
Q

Pathology of head and neck cancer (6)

A
Squamous Cell Cancer 90%
Adenocarcinoma
Small Cell Carcinoma
Sarcoma
Lymphoma
Skin
• Squamous Cell Carcinoma
• Basal Cell Carcinoma
• Malignant Melanoma
• Merkel Cell Tumour
41
Q

Investigations needed (5)

A
• Clinical examination
• Blood tests
• Examination under anaesthesia
• Biopsy
• Imaging
– Of primary: MRI/ CT scan
– Potential sites of metastatic disease: FDG-PET scan/ CT scan thorax/CXR
42
Q

Classification of cancers by (3)

A

Type of cancer cell
Grade
TNM staging

43
Q

Classification of cancers: type of cancer cell (4)

A
  • Glandular - Adenocarcinoma
  • Skin/mucosa - Squamous cell carcinoma
  • Connective tissues - Sarcoma
  • Small Cell - Small cell Carcinoma
44
Q

Human Papilloma Virus Background (4)

A
• DNA virus
• Orogenital transmission
• Cervical &amp; oropharyngeal SCC
 Considered a distinct disease entity
– Younger patients <50 yrs of age
– Non smokers &amp; reduced alcohol exposure
45
Q

HPV response to chemoradiation (2)

A

Really high!
Metanalysis: HPV +ve 28% reduced risk of dying
49% reduced risk of local recurrence

46
Q

Overview of H&N management (6)

A
• Aim is to maximise loco-regional control &amp; survival
with minimal functional damage
• Multidisciplinary approach
• Early nutritional assessment
• Dental assessment
• Speech &amp; language assessment
• Psychological support
47
Q

Disease stage: early (4)

A

Stage I-II
• Single modality approach
• Favourable prognosis
• Exception = nasopharynx

48
Q

Disease stage: late (6)

A
Stage III - IV, M0
• Majority of workload
• Requires multidisciplinary
approach
• Potentially curable
• Significant sequelae –
acute &amp; late
• In oral cavity usually means
combined treatment
surgery + Chemo RT
49
Q

What is radiotherapy? (5)

A

• The use of x-rays (ionising radiation) to treat cancer
• Energy is higher in a therapeutic setting as opposed
to diagnostic setting
-diagnostic x-rays – up to 150kV
-therapeutic photons – 80kv-20MV
• The amount of radiation absorbed by the tissues is
called the radiation dose (or dosage).
• The unit of RT = a Gray (Gy)
• Given in up to 50% of cancer patients in the UK

50
Q

How does radiotherapy work? (6)

A
• Ionising radiation interacts with water molecules to free radicals
• Free radicals cause DNA damage
• Malignant &amp; normal cells are damaged
• Damage to normal cells
– side-effects of radiotherapy
• Normal cells can repair if
tolerance not exceeded
• Oxygen dependent
51
Q

Considerations prior to radiotherapy (3)

A
Nutritional requirements
– Feeding tube
Dental assessment
– Dental assessment &amp; treatment
Speech &amp; swallowing assessment
– Mouth &amp; jaw exercises
52
Q

Radiotherapy: treatment delivery (7)

A
  1. Immobilisation device made – Perspex head shell
    • To minimise movement during RT & ensure accurate
    reproducibility in treatment set-up
    • Reference marks
  2. Localisation of tumour volume
    • Clinical exam, radiology & knowledge of possible routes of spread
    • CT scan or x-ray fluoroscopy
  3. Defining target volume & critical structures
    • Includes tumour volume plus a margin of normal tissue
    • Critical structures include spinal cord, brain stem, eyes etc
  4. Define RT fields & treatment plan
    • Dosimetrists & physicists
  5. Prescribe dose & fractionation schedule
    • Depends on site and intent of treatment
  6. Verification during treatment
    • To ensure the fields are accurate
    • May need adjustments during treatment
  7. Review of patient during treatment
    • Nutrition – weekly dietetic review
    • Commencing PEG nutrition
    • Side-effects
53
Q

Planning radiotherapy (4)

A
• The area to be treated is
often close to vital
structures
– spinal cord, optic chiasm,
eyes &amp; brain
• Need to keep patient very
still &amp; reproduce same
position each day of
treatment
• Patient is immobilised using
a head shell
• CT Planning scan
54
Q

Dose of radiotherapy (3)

A

• Small volume e.g. T1 N0 larynx or oropharynx
• Safe to treat with larger fraction size over shorter period of
time e.g. 55Gy in 20 fractions over 4 weeks
• Standard volumes of all H&N sites
• Radical – 66-70Gy in 33-35 fractions over 6.5-7 weeks
• Post-op/adjuvant – 60Gy in 30 fractions over 6 weeks
• Palliation
• Generally 30-45Gy in 10-15 fractions over 2-3 weeks
• Generally give >2Gy/# size

55
Q

Side effects of radiotherapy divided into (6)

A
• Early (acute)
– develop during or shortly after RT
– very common
– nearly always resolve
• Late (chronic)
– develop months to years (>40yrs) after RT
– very rare
– irreversible &amp; often severe
56
Q

Early effects of radiotherapy (lots)

A

• General – nausea, lethargy, oedema
• Skin – redness, blistering/moist desquamation
• Mucosal surfaces – mucositis, ulceration, reduced taste,
dysphagia
• Salivary function – sticky, dry
• Hair- loss in treated area
• Oesophagus- sore swallowing
• Lungs – pneumonitis ( dry cough, breathlessness)
• Bowel- diarrhoea, abdominal pain, nausea
• Bladder- frequency, cystitis type symptoms
• Bone marrow – decrease in blood counts
• Neurological - Lhermitte’s Syndrome

57
Q

Late effects of radiotherapy (lots)

A

• Skin – telangiectasia, fibrosis, necrosis
• Scalp –permanent hair loss with high dose
• Eyes – cataracts, reduced vision
• Lung – fibrosis, breathlessness
• Oesophagus, bowel – strictures/narrowing
• Kidneys – hypertension, renal failure
• Brachial plexus, spinal cord – sensory and motor impairment
of limbs – swelling
• Endocrine – hypothyroidism, growth hormone deficiency,
premature menopause
• Gonads – infertility, impotence
• Bone – impaired growth in children, necrosis
• Second malignancies

58
Q

Adjuvant RT following surgery for who? (1)

A

For patients considered to be at high risk of

locoregional recurrence

59
Q

Adjuvant RT following surgery: risk factors are

A
Primary disease
-involved or close margins
-advanced T stage
-lymphovascular invasion
-perineural invasion
LN disease
-extracapsular LN spread
-LN >3cm in size
->1 LN level involved
->2LN involved
60
Q

Palliation: chemotherapy (4)

A
• Require reasonable PS (WHO 0-2)
• Useful in palliation of symptoms
– Pain
– Difficulty with speech / swallow
– Halitosis due to tumour
– Ulcerating tumour / nodal mass
• Prolongs life by 10 weeks cf to BSC
– Morton, 1985
• Untreated median survival = 4 months
61
Q

Palliative RT (5)

A

Used to improve the quality of life in patients with recurrent,
locally advanced or metastatic disease
• Bone & brain metastases
• Where cure is not possible
• Where patient is not fit to receive radical RT
• Compression of vital structures e.g. spinal cord, SVCO
Intent is to relieve symptoms & minimise side effects from
treatment
May prolong survival
Small number of total fractions (sessions)
Relatively low doses (some times large fraction size)

62
Q

Progress in readiotherapy technology (6)

A
• Developing Rapidly
• More accurate delivery
• Dose escalation
• Less toxicity
• Greater monitoring during treatment
• Progress
– Conformal 3D Radiotherapy
– IMRT
– Rotational Treatment: Rapid Arc
– Robotic mounted treatment machines: Cyberknife
63
Q

Future directions of head and neck management (3)

A

Develop new technologies
• Improved dose to targets areas (IMRT, RAPID ARC)
• Reduced Toxicities
New drugs
– Immunotherapy
• To improve cure rate in addition to chemoradiotehrapy
• Palliative treatment
Trials
• Standardize RT technique across UK
• Radiotherapy dose escalation to improve cure rate